The TRITON study revealed an increased risk of bleeding for those taking Effient in some patient populations based on age, weight and stroke history. "The decision is in the hands of the payer organizations now ... Payers will take a close look at the TRITON data when determining Effient's reimbursement status compared to Plavix. The data create a complex decision-making process. This is not as clear-cut as, say, Pfizer's early strategy with Lipitor." Thanks in large part to the two comparison studies named CURVES and CHALLENGE, Pfizer was able to show that Lipitor was more effective in many patient populations than the other statins on the market at the time. Full Article at PR-Inside.com